LIPELLA PHARMACEUTICALS INC. Balance Sheet
LIPO|3 years of annual SEC 10-K data (FY2022-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$3M
FY2024
Cash
$2M
Cash and equivalents
Total Debt
N/A
FY2024
Shareholder Equity
$2M
FY2024
LIPELLA PHARMACEUTICALS INC. had $3M in total assets and $2M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Cash & Equivalents | $2.2M | $3.3M | $5.1M |
| Accounts Receivable | $84.7K | $32.3K | $113.7K |
| Current Assets | $2.6M | $3.4M | $5.8M |
| PP&E (Net) | $9.9K | $12.8K | - |
| Total Assets | $2.7M | $3.6M | $6.0M |
| Current Liabilities | $754.4K | $385.4K | $1.2M |
| Shareholders' Equity | $1.9M | $3.1M | $4.7M |